{"id":7,"date":"2023-11-27T12:57:33","date_gmt":"2023-11-27T03:57:33","guid":{"rendered":"https:\/\/site.convention.co.jp\/97jgca\/en\/abstracts\/"},"modified":"2024-10-02T13:13:37","modified_gmt":"2024-10-02T04:13:37","slug":"abstracts","status":"publish","type":"page","link":"https:\/\/site.convention.co.jp\/97jgca\/en\/abstracts\/","title":{"rendered":"Call for Abstracts"},"content":{"rendered":"

Abstract Submission Period<\/h2>\n

Abstracts for oral, poster<\/h4>\n\n
Tuesday, 16th, July \u2013 <\/td>Monday, 2nd,<\/del>Tuesday, 17th, September<\/del><\/td><\/tr>\n
<\/td>Tuesday, 1st, October 2024<\/del><\/td><\/tr>\n
<\/td>

Abstract submission is now closed.
Thank you for your submission.<\/p><\/td><\/tr>\n<\/tbody><\/table><\/div><\/div>

\t\t\t

Presentation Categories<\/h2>\n

Please select the most appropriate category for your presentation.<\/p>\n

Presentation style<\/h4>\n

Oral presentation<\/p>\n<\/div>\n\t\t<\/div>

\n
\n
Symposium<\/span><\/h5>\n
\n
Digital Innovation in Gastric Cancer Science: Advances in Personalized Medicine for Gastric Cancer<\/h6>\n
<\/span>Detail<\/div>
\n With the increase in available proven anticancer drugs and the advent of molecular targeted therapies and immune checkpoint inhibitors, \npersonalized cancer chemotherapy for gastric cancer is more critical than ever.
We will present results and methods for personalizing cancer chemotherapy for gastric cancer and evaluating their outcomes.\n <\/div><\/div>\n <\/article>\n
\n
Digital Innovation in Gastric Cancer Science: Advances in Navigation Surgery<\/h6>\n
<\/span>Detail<\/div>
\n Presenting the latest knowledge on surgical methods incorporating navigation functions such as fluorescence guidance, 3D-CT, and VR imaging pre- and intra-operatively.\n <\/div><\/div>\n <\/article>\n
\n
Digital Innovation in Gastric Cancer Science: Advances in Endoscopic and Pathological Diagnosis of Gastric Cancer<\/h6>\n
<\/span>Detail<\/div>
\n Presenting the latest knowledge on AI-enhanced endoscopic and pathological diagnosis.\n <\/div><\/div>\n <\/article>\n
\n
Digital Innovation in Gastric Cancer Science: Advances in Education for Young Physicians and Surgeons<\/h6>\n
<\/span>Detail<\/div>
\n Discussing how digital innovations like web-based video tutorials, remote guidance, and AI-driven anatomical recognition have revolutionized education in endoscopic diagnosis, treatment, surgery, and perioperative management for young physicians.\n <\/div><\/div>\n <\/article>\n <\/section>\n\n
\n
Video Symposium<\/span><\/h5>\n
\n
Digital Innovation in Gastric Cancer Science: Evolution of Robotic Gastrectomy<\/h6>\n
<\/span>Detail<\/div>
\n With six years since the insurance coverage of robot-assisted gastric resection, its practice has surged. Various devices and new robotic models have been developed, enhancing the surgical techniques. We will present advanced robotic-assisted surgical techniques through videos.\n <\/div><\/div>\n <\/article>\n
\n
Digital Innovation in Gastric Cancer Science: Evolution of Endoscopic Treatment Techniques for Early Gastric Cancer<\/h6>\n
<\/span>Detail<\/div>
\n Presenting a wide range of new approaches, tips and pitfalls of techniques for early gastric cancer such as ESD, EFTR, NEWS and robot-assisted ESD through videos.\n <\/div><\/div>\n <\/article>\n <\/section>\n
\n
Panel Discussion<\/span><\/h5>\n
\n
Optimal Surgery for UM Junction Gastric Cancer: Proximal Gastrectomy vs. Distal Gastrectomy<\/h6>\n
<\/span>Detail<\/div>
\n Debating which surgery is preferable for upper and middle junction gastric cancer from the perspectives of versatility, safety, short-term outcomes, optimal dissection range, curability, function preservation, and postoperative quality of life (QOL).\n <\/div><\/div>\n <\/article>\n
\n
Optimal Treatment for Early Gastric Cancer in the Elderly: ESD vs. Reduced Surgery (Sentinel) vs. Standard Surgery<\/h6>\n
<\/span>Detail<\/div>
\n Discussing the most appropriate treatment for early gastric cancer in elderly patients (75 or 80 years and older) from the perspectives of ESD expanded resection, local resection with sentinel lymph node biopsy, or standard surgery, considering short-term and long-term outcomes and postoperative QOL.\n <\/div><\/div>\n <\/article>\n
\n
What is the Optimal Conversion Surgery?<\/h6>\n
<\/span>Detail<\/div>
\n With the advancement of chemotherapy for stage IV gastric cancer, conversion surgery has increased. However, there is no established standard for indications, timing, extent of resection, metastasectomy, and adjuvant therapy. Discussions will focus on expected R0 resection cases and the timing and extent of surgeries, aiming to converge on a standardized direction.\n <\/div><\/div>\n <\/article>\n
\n
Cross-disciplinary Treatment: Optimal Treatment for Esophagogastric Junction Cancer from the Perspectives of Gastroenterologists, Esophageal Surgeons, Gastric Surgeons, and Medical Oncologists<\/h6>\n
<\/span>Detail<\/div>
\n For esophagogastric junction cancer, there is consensus on lymph node dissection range but not on the approach method or reconstruction method, which vary by institution. Discussions will aim to unify approaches regarding ESD indications, preoperative chemotherapy, and optimal regimens.\n <\/div><\/div>\n <\/article>\n <\/section>\n
\n
Video Panel Discussion<\/span><\/h5>\n
\n
Optimal Surgery for Gastric Cancer Invading the Greater Curvature: Splenectomy vs. Splenic Hilum Lymph Node Dissection<\/h6>\n
<\/span>Detail<\/div>
\n Discussing the significance of No.10 lymph node dissection for gastric cancer invading the greater curvature through videos, focusing on the concept, key points of the surgical technique, safety, and pitfalls.\n <\/div><\/div>\n <\/article>\n <\/section>\n
\n
Workshop<\/span><\/h5>\n
\n
Clinical Research in Gastric Cancer in the Digital Innovation Era<\/h6>\n
<\/span>Detail<\/div>
\n Discussing how digital innovations, such as digital data storage facilitating big data collection and the spread of internet and web conferencing, aid in advancing multicenter collaborative clinical trials, big data-based clinical trials, and international collaborative trials.\n <\/div><\/div>\n <\/article>\n
\n
Molecular Biology and Genetics of Gastric Cancer in the Digital Innovation Era<\/h6>\n
<\/span>Detail<\/div>
\n Presenting the latest advances in\u00a0basic and clinical cancer research of gastric cancers by using innovated IT technologies.\n <\/div><\/div>\n <\/article>\n
\n
Gastric Cancer Management in the Digital Innovation Era: H. pylori-negative Gastric Cancer<\/h6>\n
<\/span>Detail<\/div>
\n Discussing strategies for future gastric cancer management considering the decline in H. pylori infection rates and the expected increase in non-H. pylori-associated gastric cancers, including diagnosis, screening, and treatment.\n <\/div><\/div>\n <\/article>\n
\n
\"Best Practices in Perioperative Management for Elderly Patients in the Digital Innovation Era<\/h6>\n
<\/span>Detail<\/div>
\n Discussing how digital innovations such as sarcopenia imaging diagnosis, risk prediction models, and patient self-management apps are integrated into perioperative management plans for elderly gastric cancer patients with unique issues such as comorbidities, sarcopenia, frailty, and dementia.\n <\/div><\/div>\n <\/article>\n
\n
Multidisciplinary Treatment for Gastric GIST in the Digital Innovation Era<\/h6>\n
<\/span>Detail<\/div>
\n Discussing the treatment outcomes of neoadjuvant chemotherapy (NAC) for large gastric GISTs, postoperative treatment strategies, and the diagnosis and treatment of imatinib-resistant GISTs, incorporating digital innovations.\n <\/div><\/div>\n <\/article>\n
\n
Innovations in Minimally Invasive Gastric Cancer Surgery in the Digital Innovation Era<\/h6>\n
<\/span>Detail<\/div>
\n Discussing the centralization of gastric cancer treatment, the continued need for laparoscopic and open surgery techniques, and the innovations in minimally invasive surgery in facilities where robotic surgery is not yet implemented or limited.\n <\/div><\/div>\n <\/article>\n
\n
Innovations in LECS\/D-LECS Techniques in the Digital Innovation Era<\/h6>\n
<\/span>Detail<\/div>
\n Discussing the innovations and advancements in LECS procedures, including indications, preoperative diagnosis, and collaboration between internal medicine and surgery, as well as innovations for duodenal tumors.\n <\/div><\/div>\n <\/article>\n
\n
Latest Treatments for Scirrhous Gastric Cancer<\/h6>\n
<\/span>Detail<\/div>
\n Discussing the challenges of diagnosing and treating scirrhous gastric cancer, including endoscopic diagnostic techniques, the necessity of staging laparoscopy, prediction of chemotherapy efficacy, surgical techniques, and perioperative treatment strategies.\n <\/div><\/div>\n <\/article>\n
\n
Addressing irAE: Diagnosis, Treatment, and Countermeasures<\/h6>\n
<\/span>Detail<\/div>
\n Discussing strategies for early diagnosis, accurate diagnosis, and management of immune-related adverse events (irAE) from immune checkpoint inhibitors, including interdisciplinary collaboration.\n <\/div><\/div>\n <\/article>\n
\n
Cutting edge of endoscopic management for adverse events related to gastric ESD\/surgery (bleeding, perforation and anastomotic leakage), including wound closure and stent placement<\/h6>\n
<\/span>Detail<\/div>
\n The usefulness of new endoscopic method such as wound closure, stent placement, etc… for management of adverse events related to gastric ESD\/surgery (delayed bleeding, perforation, or anastomotic leakage) has been reported. We would welcome presentation and sharing of these experiences, even at the case report level.\n <\/div><\/div>\n <\/article>\n <\/section>\n<\/div><\/div><\/div>

Mini Oral \/ Poster Session Categories<\/h3>\n
\n
\n
\n \n
1<\/th>Epidemiology<\/td><\/tr>\n
2<\/th>Molecular biology<\/td><\/tr>\n
3<\/th>Pathology<\/td><\/tr>\n
4<\/th>Genomics<\/td><\/tr>\n
5<\/th>Translational research<\/td><\/tr>\n
6<\/th>Biomarker<\/td><\/tr>\n
7<\/th>Tumor microenvironment<\/td><\/tr>\n
8<\/th>AI<\/td><\/tr>\n
9<\/th>Endoscopic therapy<\/td><\/tr>\n
10<\/th>Endoscopic diagnosis<\/td><\/tr>\n
11<\/th>Imaging diagnosis<\/td><\/tr>\n
12<\/th>H.pylori<\/td><\/tr>\n
13<\/th>Progression of gastric cancer<\/td><\/tr>\n
14<\/th>Rare metastasis \/ Micrometastasis<\/td><\/tr>\n
15<\/th>Intraoperative frozen section<\/td><\/tr>\n
16<\/th>Cancer stem cell<\/td><\/tr>\n
17<\/th>Clinical pathology<\/td><\/tr>\n
18<\/th>Prognostic factor<\/td><\/tr>\n
19<\/th>Precision medicine<\/td><\/tr>\n
20<\/th>Clinical study<\/td><\/tr>\n
21<\/th>Chemotherapy<\/td><\/tr>\n
22<\/th>Neoadjuvant chemotherapy<\/td><\/tr>\n
23<\/th>Adjuvant chemotherapy<\/td><\/tr>\n
24<\/th>Second-line chemotherapy<\/td><\/tr>\n
25<\/th>Third-line chemotherapy<\/td><\/tr>\n
26<\/th>Intraperitoneal chemotherapy<\/td><\/tr>\n
27<\/th>Molecular targeted therapy<\/td><\/tr>\n
28<\/th>Immunotherapy<\/td><\/tr>\n
29<\/th>Radiation therapy<\/td><\/tr>\n
30<\/th>conversion surgery<\/td><\/tr>\n
31<\/th>Surgery<\/td><\/tr>\n
32<\/th>Laparoscopic surgery<\/td><\/tr>\n
33<\/th>Robot surgery<\/td><\/tr>\n
34<\/th>Function-preserving surgery<\/td><\/tr>\n
35<\/th>Cytoreductive surgery<\/td><\/tr>\n
36<\/th>LECS<\/td><\/tr>\n
37<\/th>Surgical navigation<\/td><\/tr>\n
38<\/th>Postoperative functional assessment<\/td><\/tr>\n
39<\/th>Postgastrectomy syndrome<\/td><\/tr>\n
40<\/th>Perioperative management<\/td><\/tr>\n
41<\/th>Postoperative complications<\/td><\/tr>\n <\/tbody><\/table>\n <\/div>\n <\/div>\n
\n
\n \n
42<\/th>ERAS<\/td><\/tr>\n
43<\/th>Navigation Surgery<\/td><\/tr>\n
44<\/th>Peritoneal dissemination<\/td><\/tr>\n
45<\/th>CART<\/td><\/tr>\n
46<\/th>Stent placement<\/td><\/tr>\n
47<\/th>Liver metastasis<\/td><\/tr>\n
48<\/th>Recurrence<\/td><\/tr>\n
49<\/th>Early gastric cancer<\/td><\/tr>\n
50<\/th>Advanced gastric cancer<\/td><\/tr>\n
51<\/th>Scirrhous gastric cancer<\/td><\/tr>\n
52<\/th>Gastric stump carcinoma<\/td><\/tr>\n
53<\/th>Multiple gastric cancers<\/td><\/tr>\n
54<\/th>Gastric tube cancer<\/td><\/tr>\n
55<\/th>Esophago-gastric junction cancer<\/td><\/tr>\n
56<\/th>Gastric cancer in elderly patients<\/td><\/tr>\n
57<\/th>AFP-producing gastric cancer<\/td><\/tr>\n
58<\/th>EBV-related gastric cancer<\/td><\/tr>\n
59<\/th>Gastrointestinal stromal tumor<\/td><\/tr>\n
60<\/th>Malignant lymphoma<\/td><\/tr>\n
61<\/th>Gastric neuroendocrine tumor<\/td><\/tr>\n
62<\/th>Guidelines<\/td><\/tr>\n
63<\/th>Clinical pathway<\/td><\/tr>\n
64<\/th>Postoperative surveillance<\/td><\/tr>\n
65<\/th>Long-term survival case after chemotherapy<\/td><\/tr>\n
66<\/th>NST<\/td><\/tr>\n
67<\/th>Outcome<\/td><\/tr>\n
68<\/th>QOL assessment<\/td><\/tr>\n
69<\/th>Cachexia<\/td><\/tr>\n
70<\/th>Nutrition<\/td><\/tr>\n
71<\/th>Obesity<\/td><\/tr>\n
72<\/th>Case report<\/td><\/tr>\n
73<\/th>Japanese Classification of Gastric Carcinoma<\/td><\/tr>\n
74<\/th>Multidisciplinary treatment<\/td><\/tr>\n
75<\/th>Palliative therapy<\/td><\/tr>\n
76<\/th>Team approach<\/td><\/tr>\n
77<\/th>Patient Advocacy<\/td><\/tr>\n
78<\/th>MDT conference<\/td><\/tr>\n
79<\/th>Medical cooperation<\/td><\/tr>\n
80<\/th>Oral care<\/td><\/tr>\n
81<\/th>EFTR<\/td><\/tr>\n
82<\/th>Others<\/td><\/tr>\n <\/tbody><\/table>\n <\/div>\n <\/div>\n<\/div><\/div><\/div>
\t\t\t

Abstract Acceptance or Rejection<\/h2>\n

Please note that the decision on abstract acceptance\/rejection is left to the sole discretion of the Congress President.<\/u><\/p>\n<\/div>\n\t\t<\/div>

\t\t\t

Abstract Submission<\/h2>\n

Language for abstract<\/h3>\n

English<\/p>\n<\/div>\n\t\t<\/div>

\t\t\t

Language for presentation<\/h3>\n

English<\/p>\n<\/div>\n\t\t<\/div>

\t\t\t

Language for presentation slides<\/h3>\n

English<\/p>\n<\/div>\n\t\t<\/div>

\t\t\t

The number of characters<\/h3>\n

Title: up to 100 characters (including spaces)
\nAbstract: up to 1600 characters (including spaces)<\/p>\n<\/div>\n\t\t<\/div>

\t\t\t

Conflict of Interest Disclosure<\/h2>\n

The author is required to report applicable COI (Conflict of Interest) by completing the “Conflict of Interest Disclosure” part in the Abstract Submission process.<\/p>\n

\n
\n If there is no COI to disclose<\/a>\n <\/div>\n
\n If there is any COI to disclose<\/a>\n <\/div>\n<\/div>\n<\/div>\n\t\t<\/div><\/div><\/div>
\t\t\t

Abstract Submission<\/h2>\n<\/div>\n\t\t<\/div>
\t\t\t

Abstract Submission<\/a><\/p>\n<\/div>\n\t\t<\/div><\/div>

\t\t\t

Confirmation \/ Modification<\/a><\/p>\n<\/div>\n\t\t<\/div><\/div><\/div><\/div>

\t\t\t

Inquiries<\/h2>\n

Secretariat of 97th Annual Meeting of The Japanese Gastric Cancer Association<\/b>
\nc\/o Japan Convention Services, Inc.
\n14F Daido Seimei Kasumigaseki Bldg.
\n1-4-2, Kasumigaseki, Chiyoda-ku,
\nTokyo 100-0013, Japan
\nE-mail:\u00a0endai-97jgca@convention.co.jp<\/p>\n<\/div>\n\t\t<\/div>